logo
Plus   Neg
Share
Email

Xenon Pharmaceuticals Inc. (XENE) Has Risen To A New High On Study Results

Xenon Pharmaceuticals Inc. (XENE) presented positive interim data from its ongoing XEN1101 Phase 1 clinical trial at a conference in Madrid.

Xenon Pharmaceuticals gapped open higher Tuesday morning and is now up 0.43 at $6.43 on above average volume. The stock has risen to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>